Aquestive Therapeutics, Inc.

AQST

NASDAQ

Healthcare

Drug Manufacturers - Specialty & Generic

Warren, NJ, US142 employeesaquestive.com

$4.14

+0.01(0.24%)

Mkt Cap $411M

$2.22

$7.49

52-Week Range

At a Glance

AI-generated

Aquestive Therapeutics reported a net loss of $83.8 million for fiscal year 2025, driven by total costs and expenses of $115.6 million which significantly exceeded revenues of $44.5 million.

Revenue breakdown: Manufacture And Supply Revenue (71.3%), License And Royalty Revenue (16.8%), Royalty (8.8%).

8-K

Aquestive Therapeutics announced the successful completion of a Type A meeting with the FDA regarding the resubmission of its Anaphylm NDA, reaffirming its guidance to resubmit in Q3 2026.

$411M

Market Cap

$36M

Revenue

-$68M

Net Income

Employees142

Fundamentals

How The Business Makes Money

Revenue by Segment

Manufacture And Supply Revenue71.3%($80M)

License And Royalty Revenue16.8%($19M)

Royalty8.8%($10M)

Co Development And Research Fees2.8%($3M)

Proprietary Product Revenue0.3%($315.0K)

Revenue by Geography

US68.1%($70M)

Non Us31.9%($33M)

Activity

What Changed Recently

Management Change

Mar 19, 2026

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 16,

Material Agreement

Mar 3, 2026

Entry into a Material Definitive Agreement. On March 3, 2026, Aquestive Therapeutics, Inc. (the "Company") entered into Amendment No. 1 (the "Amendment") to the

Regulation FD

Mar 29, 2026

(including Exhibit 99.1) shall not be deemed to be “filed” for purposes of, or otherwise subject to the liabilities of, Section 18 of the Securities Exchange Ac

Regulation FD

Feb 25, 2026

(including Exhibit 99.1) shall not be deemed to be “filed” for purposes of, or otherwise subject to the liabilities of, Section 18 of the Exchange Act of 1934,

Regulation FD

Feb 1, 2026

(including Exhibits 99.1 and 99.2) shall not be deemed to be “filed” for purposes of, or otherwise subject to the liabilities of, Section 18 of the Securities E

Peer Companies

Company	Price	Change	Market Cap	P/E
ERASErasca, Inc.	$17.79	+7.14%	$5.5B	-32.6
MLTXMoonLake Immunotherapeuti...	$17.39	+5.30%	$1.2B	-4.8
ARVNArvinas, Inc.	$10.83	-4.41%	$696M	-8.3
ESPREsperion Therapeutics, In...	$2.62	+0.19%	$544M	-27.3
OFIXOrthofix Medical Inc.	$11.53	-0.73%	$463M	-5.2
EBSEmergent BioSolutions Inc...	$8.20	-2.15%	$425M	8.2
SIGASIGA Technologies, Inc.	$5.22	+1.06%	$374M	—
SNDLSNDL Inc.	$1.36	+2.26%	$353M	-31.2

Analyst View

Company Profile

CIK0001398733

ISINUS03843E1047

CUSIP03843E104

Phone908 941 1900

Address30 Technology Drive, Warren, NJ, 07059, US

SEC EDGAR